Cardiovascular Diseases (CVD) are the major cause of death worldwide, accounting for an increasing prevalence of death which will reach 23.6 million of affected persons in the 2030, [1] and for an incidence varying from 3.9 per 1,000 person-years to 37.1 per 1,000 person-years according to the presence of cardiovascular risk factors [2].Such data are not limited to the Western countries' populations: emerging countries declare increasing CVD prevalence and incidence which are able to reduce the overall quality of life and lifespan of their inhabitants [3,4].The emergency department, in agreement with the cardiology department, is the place where all the acute aspects of CVD are gathered. Acute Coronary Syndromes (ACS) in the form of unstable angina, non-ST (NSTEMI) or ST (STEMI) segment elevation myocardial infarction, acute heart failure, pulmonary embolism, etc. are often observed in the emergency and cardiology departments. Due to the high amount of CVD, the need to early detect de-compensated conditions of individuals forced physicians to adopt tools and biochemical parameters able to detect the early sign of health instability.Biomarkers are the most important, immediate and easy tools adopted in order to detect the early signs of CVD and their acute expression [5][6][7][8][9]. Furthermore, their predictive value is fundamental in order to better evaluate the patients and their future cardiovascular risk.According to ACS conditions, troponins are the best biomarkers already established for the detection of such conditions [5,6]. Roy et al. which compared the most novel biomarkers (heart fatty acid binding protein [HFABP]-1 and copeptin and troponin) and the best troponins assays in 850 patients presenting at the emergency department for acute chest pain. According to the 68 patients who were admitted at the cardiology department with the diagnosis of myocardial infarction, the authors found an AUC ranging from 0.92 to 0.94 for troponins assays, which were data strongly higher than those coming from the AUC for HFABP-1 [0.84 (0.77 to 0.90)] or copeptin [0.62 (0.57 to 0.68)]. In particular, the novel high sensitive troponins I (hsTnI) assays demonstrate a sensibility for the detection of myocardial infarction equal to 97% (95% CI: 91-99%), specificity equal to 81% (95% CI: 76-86%), a positive predictive value equal to 63% (95% CI: 55-71%) and a negative predictive value equal to 99% (95% CI: 96-100%) [12]. Creatin kinase (CK) is another biomarker which helps physicians in the acute cardiovascular setting [5]. Chin et al. [13] recently demonstrated that both peak CK-MB and peak troponin I were independently related to the in-hospital mortality of a dataset of patients suffering from acute myocardial infarction and gathered in the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). They observed that CK-MB were able to slightly increase the in-hospital mortality rate prediction of both STEMI (model C-statistic...